- Peptinovo Biopharma has entered a partnership with Alcami to lyophilise its PALM nanotechnology therapeutic, creating a shelf-stable formulation suitable for global distribution.
- The collaboration supports Peptinovo’s plan to begin human clinical trials in Australia later this year.
Peptinovo Biopharma has announced a strategic partnership with Alcami Corporation to advance its PALM nanotechnology platform toward commercial readiness. The agreement centres on Alcami performing lyophilisation to convert Peptinovo’s therapeutic formulation into a stable powder for global distribution.
Peptinovo stated that lyophilisation will remove the need for cold-chain logistics and reduce shipping complexity. The company said the powdered product can be reconstituted at the point of care with sterile saline or water, supporting worldwide access.
“This partnership with Alcami is another milestone in proving the strength, scalability and real-world viability of our PALM nanotechnology.”
Steve Tokarz, CEO of Peptinovo Biopharma
The proprietary PALM (Peptide-Amphiphile Lipid Micelle) technology is designed to deliver chemotherapy agents directly to tumours to minimise toxicity. Peptinovo is preparing to start human clinical trials in Australia later this year. Alcami said its analytical and formulation capabilities would support the development programme.
“Alcami’s mission is to help innovative companies like Peptinovo deliver transformative therapies to patients faster.”
Timothy Compton, Chief Strategy Officer at Alcami
The partnership follows Peptinovo’s recent progress with Ardena in Belgium, which established scalable manufacturing of the PALM technology for clinical supply. Alcami’s involvement supports the next stage of development by producing a formulation suitable for broad distribution.
